Astellas Responds To “Approvable” Letter For Prograf MR Kidney Transplant Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Tokyo-based pharma is still examining what action to take regarding a “not approvable” letter for a heart transplant indication.
You may also be interested in...
Astellas Sees Further FDA Action On Prograf MR In Early 2008
Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.